A detailed history of Canton Hathaway, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Canton Hathaway, LLC holds 695 shares of BMY stock, worth $40,469. This represents 0.01% of its overall portfolio holdings.

Number of Shares
695
Previous 695 -0.0%
Holding current value
$40,469
Previous $29,000 24.14%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 17, 2022

SELL
$0.13 - $76.84 $65 - $38,420
-500 Reduced 41.84%
695 $49,000
Q4 2021

Jan 06, 2022

SELL
$53.63 - $62.52 $1.36 Million - $1.58 Million
-25,343 Reduced 95.5%
1,195 $75,000
Q3 2021

Oct 14, 2021

SELL
$59.17 - $69.31 $266,560 - $312,241
-4,505 Reduced 14.51%
26,538 $1.57 Million
Q2 2021

Jul 08, 2021

SELL
$61.91 - $67.42 $51,942 - $56,565
-839 Reduced 2.63%
31,043 $2.07 Million
Q1 2021

Apr 14, 2021

BUY
$59.34 - $66.74 $390,575 - $439,282
6,582 Added 26.02%
31,882 $2.01 Million
Q4 2020

Feb 03, 2021

BUY
$57.74 - $65.43 $526,011 - $596,067
9,110 Added 56.27%
25,300 $1.57 Million
Q3 2020

Nov 09, 2020

BUY
$57.43 - $63.64 $590,954 - $654,855
10,290 Added 174.41%
16,190 $976,000
Q2 2020

Jul 27, 2020

SELL
$54.82 - $64.09 $51,530 - $60,244
-940 Reduced 13.74%
5,900 $347,000
Q1 2020

May 06, 2020

BUY
$46.4 - $67.43 $43,616 - $63,384
940 Added 15.93%
6,840 $381,000
Q4 2019

Jan 10, 2020

SELL
$49.21 - $64.19 $42,812 - $55,845
-870 Reduced 12.85%
5,900 $379,000
Q3 2019

Oct 11, 2019

BUY
$42.77 - $50.71 $268,167 - $317,951
6,270 Added 1254.0%
6,770 $343,000
Q3 2018

Oct 12, 2018

BUY
$55.19 - $62.25 $27,595 - $31,125
500 New
500 $31,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Canton Hathaway, LLC Portfolio

Follow Canton Hathaway, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Canton Hathaway, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Canton Hathaway, LLC with notifications on news.